TSHA - NASDAQ
Taysha Gene Therapies, Inc.
$5.79
+1.7%Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
At a Glance
Live SnapshotTaysha Gene Therapies, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Taysha Gene Therapies, Inc. Income Statement
TSHA • NASDAQ
| Taysha Gene Therapies, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
9.8M | 8.3M | 15.5M | 2.5M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(1.1M) | (0.0) | (0.0) | (2.5M) | (0.0) | (9K) | (0.0) | |
8.6M | 8.3M | 15.5M | 15K | 0.0 | -9K | 0.0 | |
OPERATING INCOME | |||||||
(119.1M) | (99.8M) | (87.9M) | (126M) | (173.3M) | (43M) | (1.1M) | |
(32.7M) | (29M) | (30M) | (34.9M) | (41.3M) | (11.1M) | (128K) | |
(86.4M) | (66M) | (56.8M) | (91.2M) | (131.9M) | (31.9M) | (987K) | |
-110.5M | -91.5M | -72.4M | -126M | -173.3M | -43M | -1.1M | |
PRE-TAX INCOME | |||||||
(63K) | (102K) | (5M) | (3.8M) | (1.4M) | (28K) | (0.0) | |
9.2M | 6.8M | -1.4M | -3.5M | -1.3M | 21K | 0.0 | |
(0.0) | (4.8M) | (1.1M) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.5M | 2.2M | -39.1M | -40M | -1.3M | -17M | 0.0 | |
-109M | -89.3M | -111.6M | -166M | -174.5M | -60M | -1.1M | |
NET INCOME | |||||||
-109M | -89.3M | -111.6M | -166M | -174.5M | -43M | -1.1M |
SEC Filings
TSHA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 16, 2025 | October 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 09, 2025 | October 09, 2025 | 2025 |
Related Guides
Continue your TSHA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.